Endpoints News 2026년 3월 27일 Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate
Endpoints News 2026년 3월 25일 Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis' Scemblix
Endpoints News 2026년 3월 23일 Novartis to invest $480M in China following AstraZeneca and Lilly pledges
Endpoints News 2026년 3월 20일 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News 2026년 3월 16일 After Novartis pact, macrocycle shop Unnatural Products gets $45M Series B
Endpoints News 2026년 2월 26일 Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Endpoints News 2026년 2월 18일 Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Endpoints News 2026년 2월 18일 Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Endpoints News 2026년 1월 13일 Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Endpoints News 2026년 1월 12일 Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s